Glucosinolates and Their Hydrolytic Derivatives: Promising Phytochemicals With Anticancer Potential DOI Open Access
Nataša Joković, Srdjan Pešić, Jelena Vitorović

et al.

Phytotherapy Research, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 27, 2024

Recent research has increasingly focused on phytochemicals as promising anticancer agents, with glucosinolates (GSLs) and their hydrolytic derivatives playing a central role. These sulfur-containing compounds, found in plants of the Brassicales order, are converted by myrosinase enzymes into biologically active products, primarily isothiocyanates (ITCs) indoles, which exhibit significant properties. Indole-3-carbinol, diindolylmethane, sulforaphane (SFN), phenethyl isothiocyanate (PEITC), benzyl isothiocyanate, allyl have shown potent effects animal models, particularly breast, prostate, lung, melanoma, bladder, hepatoma, gastrointestinal cancers. Clinical studies further support chemopreventive SFN PEITC, detoxifying carcinogens altering biochemical markers cancer patients. compounds demonstrated good bioavailability, low toxicity, minimal adverse effects, supporting potential therapeutic application. Their mechanisms include modulation reactive oxygen species, suppression cancer-related signaling pathways, direct interaction tumor cell proteins. Additionally, semi-synthetic GSLs been developed to enhance efficacy. In conclusion, offer both warranting clinical investigation optimize application treatment.

Language: Английский

Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems DOI Creative Commons
Matteo Perra, Ines Castangia, Matteo Aroffu

et al.

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: Jan. 21, 2025

Cancer remains the second leading cause of death globally, driving need for innovative therapies. Among natural compounds, maytansinoids have shown significant promise, contributing to nearly 25% recently approved anticancer drugs. Despite their potential, early clinical trials faced challenges due severe side effects, prompting advancements in delivery systems such as antibody-maytansinoid conjugates (AMCs). This review highlights activity maytansinoids, with a focus on AMCs designed target cancer cells specifically. Preclinical and studies show that AMCs, including FDA-approved drugs like Kadcyla Elahere, effectively inhibit tumor growth while reducing systemic toxicity. Key developments include improved synthesis methods, linker chemistry payload design. Ongoing research aims enhance safety efficacy integrate nanotechnology drug delivery, identify novel therapeutic targets. These hold potential transform maytansinoid-based treatments future.

Language: Английский

Citations

1
Harnessing the anticancer potential of Piper nigrum: a synergistic approach to chemotherapy enhancement and reduced side effects DOI Creative Commons
Hesti Lina Wiraswati, Ilma Fauziah Ma’ruf, Nur Akmalia Hidayati

et al.

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: Jan. 6, 2025

Cancer therapy continues to face critical challenges, including drug resistance, recurrence, and severe side effects, which often compromise patient outcomes quality of life. Exploring novel, cost-effective approaches, this review highlights the potential Piper nigrum (black pepper) extract (PNE) as a complementary anticancer agent. nigrum, widely available spice with rich history in traditional medicine, contains bioactive compounds such piperine, have demonstrated significant activities cell cycle arrest, apoptosis induction, inhibition tumor growth metastasis. The evaluates recent findings from vitro, vivo, clinical studies, emphasizing PNE's capacity enhance efficacy conventional chemotherapeutic agents while mitigating their effects. Key mechanisms underlying these effects include oxidative stress modulation, suppression pro-metastatic factors, synergistic interactions established drugs like doxorubicin paclitaxel. These suggest that PNE could play pivotal role overcoming chemoresistance improving therapeutic outcomes. Furthermore, benefits resource-limited settings, where cost cancer treatments restricts access. However, challenges compositional variability, limited bioavailability, need for standardization validation be addressed advance integration into basic oncology. By providing comprehensive analysis its adjuvant therapy, provides new insight exploitation improve treatment reducing Future research directions are discussed address current limitations facilitate translation.

Language: Английский

Citations

0
Natural Chemical Constituents and Polymer Used in to Reduce PCOS Pain DOI Creative Commons

Prakash Pralhad Sarwade,

B Dhanasree,

Kavita Narayan Gaisamudre

et al.

Journal for Research in Applied Sciences and Biotechnology, Journal Year: 2025, Volume and Issue: 4(1), P. 88 - 99

Published: Feb. 26, 2025

The complex metabolic and endocrine disorder known as polycystic ovarian syndrome (PCOS) is characterised by anovulation, infertility, obesity, insulin resistance, ovaries. Factors that predispose women to encompass dietary lifestyle decisions, environmental pollutants, genetic predisposition, gut dysbiosis, alterations in neuroendocrine function, excess adiposity. Hyperinsulinemia, oxidative stress, hyperandrogenism, inadequate folliculogenesis, irregular menstrual periods are symptoms may arise from these variables, potentially contributing an escalation of syndrome. Pathogenic dysbiosis the microbiota have a role aetiology (PCOS). Immature oocytes, inflammation, resveratrol pathological features PCOS be ameliorated supplementation with natural compounds such polyphenols, quercetin, resveratrol, flavonoids, vitamin C, gamma-linolenic acid, piperine, omega-3 fatty acids, along semi-synthetic polymers. This review encapsulates current understanding efficacy chemical treatment PCOS.

Language: Английский

Citations

0
Piperine derivative, (2E,4E)-5-(benzo[d][1,3]dioxol-5-yl)-N-(2-hydroxyphenyl)penta-2,4-dienamide, exerted Cytotoxic activity toward MCF-7 Breast Cancer Cells via Apoptosis: Gene expression and Biomolecular change study DOI
Santi Phosri, Alisa Naladta, Nuttinee Teerakulkittipong

et al.

Biochemical and Biophysical Research Communications, Journal Year: 2025, Volume and Issue: 766, P. 151895 - 151895

Published: April 25, 2025

Language: Английский

Citations

0
Current mechanistic insights into Withaferin A: a promising potential adjuvant anticancer agent from Withania somnifera DOI
Muhammad Nisar, Chunpeng Wan, Dietrich Büsselberg

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 30, 2024

Language: Английский

Citations

0
Glucosinolates and Their Hydrolytic Derivatives: Promising Phytochemicals With Anticancer Potential DOI Open Access
Nataša Joković, Srdjan Pešić, Jelena Vitorović

et al.

Phytotherapy Research, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 27, 2024

Recent research has increasingly focused on phytochemicals as promising anticancer agents, with glucosinolates (GSLs) and their hydrolytic derivatives playing a central role. These sulfur-containing compounds, found in plants of the Brassicales order, are converted by myrosinase enzymes into biologically active products, primarily isothiocyanates (ITCs) indoles, which exhibit significant properties. Indole-3-carbinol, diindolylmethane, sulforaphane (SFN), phenethyl isothiocyanate (PEITC), benzyl isothiocyanate, allyl have shown potent effects animal models, particularly breast, prostate, lung, melanoma, bladder, hepatoma, gastrointestinal cancers. Clinical studies further support chemopreventive SFN PEITC, detoxifying carcinogens altering biochemical markers cancer patients. compounds demonstrated good bioavailability, low toxicity, minimal adverse effects, supporting potential therapeutic application. Their mechanisms include modulation reactive oxygen species, suppression cancer-related signaling pathways, direct interaction tumor cell proteins. Additionally, semi-synthetic GSLs been developed to enhance efficacy. In conclusion, offer both warranting clinical investigation optimize application treatment.

Language: Английский

Citations

0